Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers  

作　　者：Ziqi Wan Yang Chen Junling Zhuang Miao Chen Shuyang Zhang Bing Han 

机构地区：[1]Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China [2]Eight-Year Program of Clinical Medicine,M.D.Program,Department of Clinical Medicine,Peking Union Medical College,Beijing 100005,China [3]Department of Cardiology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China

出　　处：《Chinese Medical Journal》2023年第9期1120-1122,共3页中华医学杂志（英文版）

基　　金：Chinese Acadmy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS 2021-1-I2M-003);PUMCH National High-Level Hospital Clinical Research Funding(Nos.2022-PUMCH-C-026,2022-PUMCH-D-002,2022-PUMCH-B-046)

摘　　要：To the Editor:Myelosuppression is one of the most common side effects of chemotherapy.Some patients would develop long-lasting aplastic anemia(AA)even after stopping chemotherapy for over three months,due to persistent destruction of the bone marrow.As a thrombopoietin-receptor agonist,eltrombopag(EPAG)has been widely used in patients with thrombocytopenia from various origins,[1]including those with AA secondary to chemotherapy.However,both EPAG and cyclosporin A(CsA)have been reported to possibly induce the expansion of abnormal clones or controversially increase the risk of neoplasms.[2]Thus,the challenge was to treat severe cytopenia while preventing cancer relapse.Our study reported the efficacy and safety of EPAG with or without CsA for patients with AA secondary to chemotherapy,in an attempt to find solutions to these difficulties.

关 键 词：ANEMIA CHEMOTHERAPY CYCLOSPORIN 

分 类 号：R730.53[医药卫生—肿瘤] R556.5[医药卫生—临床医学]